Clinical trials: MPN
Myeloproliferative Neoplasm, MPN
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
- Conditions
- Myeloproliferative Neoplasm, MPN, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT05123365
- Testing
- N-Acetylcysteine
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Myelodysplastic Syndromes
Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)
This is a phase II, single-group pilot study to evaluate efficacy and methylation. This study's overarching aim is to evaluate the systemic effects of black raspberries in patients with myelodysplastic syndrome or myelodysplastic…
- Trial name
- NCT03140280
- Testing
- Freeze-Dried Black Raspberry Powder
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ehab L Atallah
Myelofibrosis, Essential Thrombocythemia
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period.
- Conditions
- Myelofibrosis, Essential Thrombocythemia, MPN
- Trial name
- NCT05025488
- Testing
- Peptide-based vaccine, Poly ICLC
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Marina Kremyanskaya
Myeloproliferative Neoplasm
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferative neoplasms.
- Trial name
- NCT04103645
- Testing
- Vactosertib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Acne
Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne
A growing body of evidence suggests that the development and progression of acne are closely linked to an imbalance in the skin's microbial community.
- Trial name
- NCT07366229
- Testing
- MPN-coated engineered Lactobacillus reuteri cream, Plain Lactobacillus reuteri cream, Petrolatum-glycerin cream
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Shenzhen People's Hospital
Myeloproliferative Neoplasm
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
The purpose of this research is to study the safety and tolerability and to establish the maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for the treatment of advanced-phase MPNs.
- Trial name
- NCT05524857
- Testing
- Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Joseph Jurcic
Refractory Mycoplasma Pneumoniae Pneumonia
Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children
The purpose of this study is planned to investigate whether small doses of methylprednisolone pulse macrolide therapy can relieve symptoms,chest X-rays faster than macrolide alone therapy for refractory mycoplasma pneumoniae…
- Trial name
- MPP (NCT01217099)
- Testing
- methylprednisolone, azithromycin
- Volunteers
- 47 people
- Sponsor
- Chongqing Medical University
Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome
Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
This is a single-center randomized phase 2 open-label clinical trial.
- Conditions
- Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
- Trial name
- NCT07710534
- Testing
- Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Childhood Pneumonia, Mycoplasma Pneumonia
Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)
To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and…
- Conditions
- Childhood Pneumonia, Mycoplasma Pneumonia, Antibody-secreting Cells, Enzyme-linked Immunospot (ELISpot)
- Trial name
- myCAP (NCT03613636)
- Testing
- Enzyme-linked immunospot (ELISpot) assay [Blood]
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Mycoplasma Pneumonia, Pulmonary Tuberculosis
Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis
Several case report showed that the co-infection of Mycoplasma pneumoniae in patients with pulmonary tuberculosis. The aim of this study is to elucidate the prevalence and its clinical significance of co-infection of Mycoplasma…
- Trial name
- NCT00926601
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Myeloproliferative Neoplasm, Unclassifiable
MPN Podcast Pilot Study
Enrolled MPN patients will participate in a podcast intervention via a smartphone app. They will listen to 60 minutes per week of podcasts through this app, which consist of cancer-related health education material.
- Trial name
- NCT03907774
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Arizona State University
Polycythemia Vera, ET (Essential Thrombocythemia)
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV)…
- Conditions
- Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET)
- Trial name
- NCT07362225
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- MPN Research Foundation
Anemia, Myelodysplastic Syndromes
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.
- Trial name
- NCT05237713
- Testing
- Canakinumab Injection
- Where
- 3 sites in Germany
- Volunteers
- 10 people
- Sponsor
- University of Leipzig
Phase II, Imetelstat
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms
To learn if imetelstat can help to control MDS/MPNs.
- Conditions
- Phase II, Imetelstat, Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
- Trial name
- NCT07549451
- Testing
- Imetelstat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- FREEDOM (NCT03755518)
- Testing
- FEDRATINIB
- Where
- 35 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Celgene
Mycoplasma Pneumoniae Pneumonia
Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia
Mycoplasma pneumoniae is one of the most common causes of community-acquired pneumonia in children. The clinical course is typically self-limited and benign; however, rare cases of severe pneumonia can develop despite appropriate…
- Trial name
- NCT02618057
- Testing
- Prednisolone, Levofloxacin
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Seoul National University Hospital
Polycythemia Vera (PV), Myelofibrosis (MF)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and…
- Conditions
- Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
- Trial name
- NCT07469891
- Testing
- PRT12396
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Prelude Therapeutics Incorporated
Atypical Pneumonia
Treatment and Vaccine Development of Mycoplasma Pneumoniae
A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.
- Trial name
- NCT03911440
- Testing
- Doxycycline, Azithromycin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
MPN, Essential Thrombocythemia
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is…
- Trial name
- FAST (NCT02611973)
- Testing
- Aspirin therapy interruption, Usual treatment by aspirin 100 mg/d in the active comparator arm, No interruption of aspirin in the Observational arm
- Where
- France
- Volunteers
- 2,250 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris